Oncopeptides benefits from drawing on the world-class knowledge and experience of a it’s co-workers, led by the management team working from the Company Headquarters in Stockholm, Sweden. A US-based Chief Commercialisation Officer and a US-based Chief Scientific Officer also forms part of the Oncopeptides management team.

Throughout the company’s life it has benefitted from consistency in both the core management team and board membership as well as in its wider network of collaborators. Oncopeptides also has continued links to the researchers that initially developed melflufen (Ygalo®) as well as to the founders of the company.

In addition to its core team and the standing network of collaborators, Oncopeptides has established further collaborative relationships with leading researchers and institutions in Europe and the US, including the Harvard Medical School – Dana Farber Cancer Institute.

The nature of the clinical process means that Oncopeptides’ collaborators work principally with the design, planning and project management of clinical studies and the consequent regulatory engagement. Each new project requires collaborators with specialist knowledge in the area and studies are generally carried out by clinical research organisations.